Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 7
Submit an article Journal homepage
54
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Mdr1 Gene Expression and Mutations in Ras Proto-oncogenes in Acute Myeloid Leukemia

Markus Schaich Department of Medicine I, University Hospital C.G. Carus, Fetscherstr. 74, 01307 Dresden, Germany
&
Thomas Illmer Department of Medicine I, University Hospital C.G. Carus, Fetscherstr. 74, 01307 Dresden, Germany
Pages 1345-1354 | Published online: 01 Jul 2009

  • Schaich, M., Ritter, M., Illmer. T., Lisske, P., Thicde. C., Schakel, U., Mohr, B., Ehninger, G. and Neubauer, A. (2001) "Mutations in ras pfoto-oncogenes are associated with lower mdrl gene expression in adult acute myeloid leukaemia", British Journal of Haematology 112, 300-307.
  • Biedler, J.L. and Riehm. H. (1970) "Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioaulographic, and cytogenetic studies". Cancer Research 30, 1174-1184.
  • Dano, K. (1973) "Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells", Biochimica et Biophysica Acta 323, 466-483.
  • Skovsgaard, T. (1978) "Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascitcs tumor cells". Cancer Research 38, 4722-4727.
  • Juliano, R.L. and Ling, V. (1976) "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants", Biochimica et Biophysica Acta 455, 152-162.
  • Chin, J.E., Soffir. R., Noonan, K.E., Choi, K. and Roninson. l.B. (1989) "Structure and expression of the human MDR (P-glycoprotein) gene family". Molecular and Cellular Biology 9, 3808 3820.
  • Gros, P., Ben Neriah, Y.B., Croop, J.M. and Housman. D.E. (1986) "Isolation and expression of a complementary DNA that confers multidrug resistance", Nature 323, 728-731.
  • Trent, J.M. and Witkowski. C.M. (1987) "Clarification of the chromosomal assignment of the human P-glycoprotein/mdrl gene: possible coincidence with the cystic fibrosis and c-met oocogene", Cancer Genetics and Cvtagenetics 26, 187-190.
  • Chen, C.J., Clark. D., Üeda, K., Pastan. I., Gottesman, M.M. and Roninson, l.B. (1990) "Genomic organization of the human multidrug resistance (MDR I) gene and origin of P-glycoproteins", Journal of Biological Chemistry 265, 506-514.
  • Juranka, P.p., Zastawny. R.L. and Ling. V. (1989) "P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins", FASEB Journal 3, 2583-2592.
  • Gerlach, J.H., Endicott, J.A., Juranka. P.P., Henderson, G., Sarangi, F., Deuchars, K.L. and Ling, V. (1986) "Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance", Nature 324, 485-489.
  • Homolya, L., Hollo, Z., Germann, U.A., Pastan, I. Gottesman, M.M. and Sarkadi, B. (1993) "Fluorescent cellular indicators are extruded by the multidrug resistance protein". Journal of Biological Chemistry 268, 21493-21496.
  • Raviv, Y., Pollard, H.B., Bruggemann. E.P., Pastan, I. and Gottesman, M.M. (1990) "Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells", Journal of Biological Chemistry 265, 3975-3980.
  • Higgins. C.F. and Gottesman, M.M. (1992) "Is the multidrug transporter a flippase?', Trends in Biochemical Sciences 17, 18-21.
  • Roepe, P.D. (2000) "What is the precise role of human MDRI protein in chemotherapeutic drug resistanceT', Current Pharmaceutical Design 6, 241 -260.
  • Pallis, M. and Russell, N. (2000) "P-glycoprotein plays a drugef flux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway". Blood 95, 2897-2904.
  • Cornwell, MM., Pastan, I. and Gottesman. M.M. (1987) "Certain calcium channel blockcrs bind specifically to multidrug-rcsLstam human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein", Journal of Biological Chemistry 262. 2166-2170.
  • Foxwell, B.M., Mackie, A., Ling, V. and Ryffel, B. (1989) "Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein". Molecular Pharmacology 36. 543-546.
  • Karp, J.E. (2001) "MDR modulation in acute myelogenous leukemia is it dead?". Leukemia 15, 666-667.
  • List, A.F. (1996) "Role of multidrug resistance and ils pharmacological modulation in acute myeloid leukemia". Leukemia 10, 937 942.
  • Rao, V.V., Dahlheimer. J.L., Bardgett, M.E. Snyder, A.Z., Finch, R.A., Sartorclli, A.C. and Piwnica-Worms, D. (1999) "Choroid plexus epithelial expression of MDRI P glycoprotein and multidrug resistance-associated protein contribute to the blood cerebrospinal-fluid drug-permeability barrier". Proceedings of the National Academy of Sciences of the USA 96, 3900-3905.
  • Tbiebaut, F., Tsuruo, T., Hamada. H., Gottcsman, M.M. Pastan, I. and Willingham. M.C. (1987) "Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues". Proceedings of the National Academy of Sciences of the USA 84, 7735-7738.
  • Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. and Bertino, J.R. (1989) "Multidrugresistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites". Proceedings of the National Academy of Sciences of the USA 86, 695-698.
  • Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Huber, H. and Andreeff, M. (1992) "Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype", Blood 80, 2729-2734.
  • Klimecki, W.T., Taylor. C.W. and Dalton, W.S. (1995) "Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs", Journal of Clinical Immunology 15, 152-158.
  • Chaudhary, P.M. and Roninson, I.B. (1991) "Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells". Cell 66, 85-94.
  • Marie, J.P., Zittoun, R. and Sikic, B.I. (1991) "Multidrug resistance (mdrl) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity". Blood 78, 586-592.
  • Leith, C.P., Chen. I.M., Kopecky, K.J., Appelbaum, F.R., Head. D.R., Godwin, J.E., Weick. J.K. and Willman, C.L. (1995) "Correlation of multidrug resistance (MDRI) protein expression with functional dye/drag efflux in acute myeloid leukemia by multipaiameter flow cytnmetry: identification of discordant MDR - /efflux + and MDRI +/efflux - cases", Blood 86, 2329-2342.
  • van den Heuvcl-Eibrink, M.M., van der Holt, B., te Boekhorst, P., Pieters, R., Schoestcr, M., Lowcnbcrg, B. and Sonneveld, P. (1997) "MDRl expression is an independent prognostic factor for response and survival in de now acute myetoid leukaemia", British Journal of Haematology 99, 76-83.
  • Campos, L., Guyotat, D., Archimbaud. E, Calmard-Oriol, P. Tsuruo. T., Troncy, J., Treille. D. and Fiere, D. (1992) "Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis", Blood 79, 473-476.
  • te Boekhorst, P, Uowenberg, B., van Kapel. J., Nooter. K. and Sonneveld, P. (1995) "Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myetoid leukemia". Leukemia 9, 1025-1031.
  • Illmer, T., Schaich, M., Oelschlagel, U., Nowak, R., Renner. U., Ziegs, B., Subat, S., Neubauer. A. and Ehninger. G. (1999) "A new PCR MIMIC strategy to quantify low mdrl mRNA levels in drug resistant cell lines and AML blast sample;.". Leukemia Research 23, 653-663.
  • Leith, C.P., Kopecky, K.J., Godwin, J., McConnell. T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum. F.R. and Willnian. C.L. (1997) "Acute myeloid leukemia in the elderly: assessment of rmittidrug resistance (MDRl) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study". Blood 89, 3323-3329.
  • van den Heuvel-Eibrink, M.M., Wiemer, E.A., de Boevere, M.J., van der Hott, B., Vossebeld, P.J., Pieters, R. and Sonneveld. P. (2001) "MDRl gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia", Blood 97, 3605-3611.
  • Schaich, M., Illmer. T., Schakel, U., Mohr, B., Soucck, S. and Bhninger, G. (2001) "Association of specific cytogenetic aberrations with mdrl gene expression in adult myeloid leukemia". Onkologie 24(Suppl. 6), 183a.
  • Pearson. L., Leith, C.P., Duncan, M.H., Chen. I.M., McConnell. T., Trinkaus, K., Foucar. K. and Willman, C.L. (1996) "Multidrug resistance-1 (MDRI) expression and functional dye/drug efflux is highly correlated with the t(8:21) chromosomal translocation in pediatric acute myeloid leukemia". Leukemia 10, 1274-1282.
  • Sato, H., Gottesman, M.M., Qoldstein. L.J., Pastan, I., Block. A.M. Sandberg, A.A. and Preisler, H.D. (1990) "Expression of the multidrug resistance gene in myeloid leukemias", Leukemia Research 14, 11-21.
  • Pirker, R., Wallner. J., Geissler, K., Unkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P. and Havelec, L. (1991) "MDRI gene expression and treatment outcome in acute myeloid leukemia". Journal of the National Cancer Institute 83. 708-712.
  • Lamy, T., Goasguen, J.E., Mordetet, E., Grulois. I., Dauriac, C., Drenou, B., Chaperon, J., Fauchet, R. and Ic Prise. P.Y. (1994) "P-glycoprotein (P-170) and CD34 expression io adult acute myeloid leukemia (AML)", Leukemia 8, 1879-1883.
  • Leith, C.P., Kopecky, K.J., Chen, I.M., Eijdems, L., Slovak, M.L., McConnell, T.S., Head, D.R., Weick. J., Grever, M.R., Appelbaum,. F.R and Willman, C.L. (1999) "Frequency and clinical significance of the expression of the multidrug resistance proteins MDR l/P-glycoprotcin, MRPl, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study". Blood 94, 1086-1099.
  • Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchai, S., Witz, F., Rose, C. and Guerci, O. (1995) "Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-giycoprotein expression simultaneously determined by flow cytometry". Blood 85, 2147-2153.
  • Advani, R., Visani. G., Milligan. D., Saba. H., Tallinan. M., Rowe. J.M., Wiemik, P.H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman. M., Covelli. A., Sikic. B. and Greenberg, P. (1999) 'Treatment of poor prognosis AML patients using PSC833 (valspodar) plus muoxantrone, etoposide. and cytarabine (PSC-MEC)", Advances in Experimental Medicine and Biology 457, 47-56.
  • Lee, E.J., George, S.L., Caligiuri, M., Szatrowski, T.P., Powell. B.L., Lemke, S., Dodge, R.K., Smith, R., Baer, M. and Schiffer, C. A. (1999) "Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420", Journal of Clinical Oncology 17. 2831-2839.
  • Chauncey, T.R., Rankin, C. Anderson, J.E., Chen, L., Kopecky. K.J., Godwin, J.E., Kataycio. M.E., Moore, D.F., Shurafa, M.S., Petersdorf, S.H., Kraut, E.H., Leilh. C.P, Head. D.R., Luthardt. KW., Willman. C.L. and Appelbaum. F.R. (2000) "A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using nitoxamrone. eloposidc. and the MDR modulator PSC 833: a southwest oncology group study 9617" Leukemia Research 24, 567-574.
  • List, A.F., Kopecky. K.J., Willman, C.L., Head, D.R., Persons, D.L., Slovak, M.L., Dorr. R., Karanes, C., Hyncs, H.E., Doroshow, J.H., Shurafa. M. and Appelbaum. F.R. (2001) "Benefit of cyclosporine modulation of drug resistance in patients with poorrisk acute myeloid leukemia: a Southwest Oncology Group study", Blood 98, 3212-3220.
  • Burger, H., Nooter, K., Zaman. G.J., Sonneveld. R. van Wingerden, K.E., Oostrum, R.G. and Sloter. G. (1994) "Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias". Leukemia 8, 990-997.
  • Scheper, R.J., Broxterman, H.J., Scheffer, G.L., Kaaijk. P., Dalton. W.S., van Heijningen, T.H., van Kalken, C.K., Slovak, M.L., de Vries, E.G. and van der VaIk, P. (1993) "Overexpression of a M(r) 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance". Cancer Research 53, 1475 1479.
  • Michieli, M., Damiani, D., Ermacora. A., Raspadori. D., Michelutti, A., Grimaz. S., Fanin, R., Russo, D., Lauria. F., Masolini, P. and Baccarani, M. (1997) "P-glycoprotein (POP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells", British Journal of Haematology 96. 356-365.
  • Schaich, M., Illmer, T., Seitz. G., Mohr, B., Schäkel. U., Beck. J.K and Ehninger, G. (2001) 'The prognostic value of Bel-XL gene expression for remission induction is influenced by cytogeneiics in adult acute myeloid leukemia". Haematologica 86, 470-477.
  • Beck, J., Handgretinger, R., Klingebiel, T., Dopfer, R., Schaich. M., Ehninger, G., Niethammer, D. and Gekeler. V. (1996) "Expression of PKC isozyme and MDR-associated genes in primary and relapsed stale. AML", Leukemia 10, 426-433.
  • Chaudhary, P.M. and Roninson. I.B. (1992) "Activation of MDRl (P-glycoprotein) gene expression in human cells by protein kinase C agonists". Oncology Research 4, 281-290.
  • Johnson, R.A., Incc, T.A. and Scotlo, K.W. (2001) 'Transcriplional repression by p53 through direct binding to a novel DNA element". Journal of Biological Chemistry 276, 27716-27720.
  • Hu, Z., Jin, S. and Scotto. K.W. (2000) "Transcriptional activation of the MDRI gene by UV irradiation. Role of NF-Y and SpI", Journal of Biological Chemiary 275, 2979-2985.
  • Yu.L., Wu, Q., Yang.C.P.and Horwitz, S.B. (1995)"Coordination of transcription factors, NF-Y and CYKBP beta, in the regulation of the mdrlb promoter". Cell Growth and Differentiation 6, 1505-1512.
  • Silverman. J.A. and Hill, B.A. (1995) "Characterization of the basal and carcinogen regulatory elements of the rat mdrlb promoter". Molecular Carcinogenesis 13, 50-59.
  • Zhou, G. and Kuo, M.T. (1997) "NF-kappaB-mediaied induction of mdrlb expression by insulin in rat hepaioma cells". Journal of Biological Chemistry 272, 15174-15183.
  • Ros, J.E., Schuetz. i.D., Geuken, M., Streetz. K., Moshage. H., Kuipers, K, Manns. M.P., Jansen, P.L., Trautwein. C. and Muller. M. (2001) "Induction of Mdrlb expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling". Hepatology 33. 1425- 1431.
  • Mallick, S. and Horwitz, S.B. (1997) 'Transcripuonal regulation of the murine multidrug resistance gene mdrlb by progesterone occurs via an indirect mechanism". DNA and Cell Biology 16, 807-818.
  • Jin, S. and Scotto. K.W. (1998) "Transcriptional regulation of the MDRl gene by historic aceryltransferase and deacetylase is mediated by NF-Y", Molecular and Cellular Biology 18. 4377-4384.
  • Lutterbach, B., Sun. D., Schuetz, J. and Hiebcrt. S.W. (1998) "The MYND motif is required for repression of basal transcription from the multiudrug resistance 1 promoter by the 1(8:21 ) fusion protein". Molecular and Cell Biology 18, 3604-3611.
  • Chin, K.V., Ueda, K., Pastan, I. and Gottesman, M.M. (1992) "Modulation of activity of the promoter of the human MDR1 gene by Ras and p53". Science 255, 459-462.
  • Slromskaya, T.P., Grigorian, I.A., Ossovskaya. V.S., Rybalkina. E.Y. Chuinakov. P.M. and Kopnin. B.P. (1995) "Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprolein function". FEBS Letters 368, 373-376.
  • Geyer, M. and Wininghofcr, A. (1997) 'OEFs. GAPs. GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins". Current Opinion in Structural Biology 7, 786-792.
  • Palsson, E.M., Popoff. M., Thelestam. M. and O'Neill, L.A. (2000) "Divergent roles for Ras and Rap in the activation of p38 mitogenactivated protein kinase by interleukin-1". Journal of Biological Chemistry 275. 7818-7825.
  • Ward, Y. Wang, W., Woodhouse, E., Linnoila, I., Liorta. L. and Kelly. K. (2001) "Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-spcctfic guarune exchange factor pathways", Molecular and Cellular Biology 21, 5958-5969.
  • Self. A.J., Caron, E., Paterson, H.F. and Hall, A. (2001) "Analysis of R-Ras signalling pathways", Journal of Cell Science 114. 1357-1366.
  • Ohba, Y., Mochizuki, N., Yamashita, S., Chan. A.M., Schrader. J.W., Hartori, S., Nagashima, K. and Matsuda, M. (2000), "Regulatory proteins of R-Ras. TC2l/R-Ras2. and M-Ras/RRas3", Journal of Biological Chemistry 275, 20020-20026.
  • Ehrhardl, G.R., Leslie. K.B., Lee. R, Wieler. J.S. and Schrader. J. W. (1999) "M-Ras, a widely expressed 29-kD homologue of p21 Ras: expression of a constitutively active mutant results in factorindependent growth of an interlcukin-3-dependent cell line", Blood 94, 2433-2444.
  • Brunger, A.T., Milburn, M.V., Tong, L., de Vos, A.M., Jancarik, J., Yamoizumi, Z., Nishimura. S., Ohlsuka, E. and Kirn. S.H. (1990) "Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain", Proceedings of the National Academy of Sciences of the USA 87, 4849-4853.
  • Allin, C., Ahmadian, M.R., Wittinghofer, A. and Gerwert. K. (2001) "Monitoring the GAP catalyzed H-Ras GTPase reaction at atomic resolution in real time". Proceedings of the National Academy of Sciences of the USA 98, 7754-7759.
  • Prive, G.G., Milburn, M.V., Tong, L., de Vos, A.M., Yamaizumi. Z., Nishimura, S. and Kim, S.H. (1992) "X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis", Proceedings of the National Academy of Sciences of the USA 89, 3649 3653.
  • Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmuller, L., Lautwein, A., Schmitr, F. and Wittinghofer. A. (1997) "The RasRasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants". Science 277, 333-338.
  • Sasaoka, T., Langlois, W.J., Leitner, J.W., Draznin, B. and Olefsky. J.M. (1994) "The signaling pathway coupling epidermal growth factor receptors to activation of p21ras". Journal of Biological Chemistry 269, 32621 -32625.
  • Pawson, T. and Saxton. TM. (1999) "Signaling networks-do all roads lead to the same genes?". Cell 97. 675-678.
  • Beaupre, D.M., Talpaz, M., Marini. F.C., Cristiano. R.J., Roth, J.A., Esuov, Z., Albitar, M., Freedman, M.H. and Kurzrock. R. (1999) "Autocrine interleukin-lbeta production in leukemia: evidence for the involvement of mutated RAS". Cancer Research 59, 2971-2980.
  • Rebollo, A. and Martinez. A. (1999) "Ras proteins: recent advances and new functions". Blood H 2971-2980.
  • Delgado, M.D., Vaque, J.P., Arozarena, L., Lopez-dasaca, M.A., Martinez, C., Crespo, P. and Leon, J. (2000) "H-. K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21Wafldependent mechanism", Oncogene 19, 783-790.
  • McGlyin, H., Kapclko, K., Baker. A., Burnett, A. and Padua. R.A. (1997) "Allelic loss of the FMS gene in acute myeloid leukaemia". Leukemia Research 21, 919-923.
  • Reuther, G.W., Lambert, Q.T., Caligiuri. M.A. and Der, C.J. (2000) "Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia". Molecular and Cellular Biology 20, 8655-8666.
  • Kottaridis, P.D., Gale. R.E., Frew, M.E., Harrison, G., Langabeer. S.E., Beiton. A.A., Walker, H., Wheattey, K., Bowen. D.T., Bumett, A.K., Goldstone, A.H and Linch, D.C. (2001) "The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogcnetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AMI. 10 and 12 trials''. Blood 98.1752-1759.
  • Golub, T.R., Goga, A., Barker, G.F. Afar, DE., McLaughlin, J., Bohlander, S.K., Rowley, J.D., Witte, O.N. and Gilliland. D.G. (1996) "Oligomerization of the ABL lyrosine kinasc by the Ets protein TEL in human leukemia", Molecular and Cellular Biologv 16,4107-4116.
  • Prasad, R., Gu, Y., Alder. H., Nakamura, T., Canaani. O., Saito. H. Huebner, K., Gale, R.P., Nowcll, P.C. and Kuriyama. K. (1993) "Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;l 1) chromosome translocatton", Cancer Research 53, 5624 5628.
  • Quesnel. B., Preudhomme, C., Vanrumbeke, M., Vachec. A. Lai. J.L. and Fenaux, P. (1994) "Absence of rearrangement of the neuroubromatosis 1 (NFl) gene in myelodysplastic syndromes and acute myeloid leukemia". Leukemia 8, 878-880.
  • Kourlas, P.J., Strout. M.P., Becknell. B., Veronese. M.L., Croce. C.M., Theil. K.S., Krahe. R., Ruutu. T, Knuulila, S., Bloomfield, C.D. and Caligiuri, M.A. (2000) "Identification of a gene at I Iq23 encoding a guanine nucleotide exchange factor evidence for its fusion with MLL in acute myeloid leukemia". Proceedings of the National Academy of Sciences of the USA 97, 2145-2150.
  • Reuthcr. G.W., Lambert, Q.T., Booden. M.A., Wennerberg. K., Becknell, B., Marcucci. G., Sondek. J., Caligiuri. M.A. and Der, C.J. (2001) "Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA", Journal of Biological Chemistry 276, 27145-27151.
  • Ahuja, H.G., Foti. A., Bar-Eli. M. and Clinc. M.J. (1990) "The pattern of mutalional involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing". Blood 75, 1684-1690.
  • Buhler-Leclerc, M., Gratwohl, A. and Senn. H.P. (1993) "Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carrying an activating N-ras mutation". British Journal of Haematology 84, 443-450.
  • Cascy, G., Rudzki, Z., Roberts, M., Hutchins, C. and luttner, C.(1993) "N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease", Pathology 25, 57-62.
  • Coghlan, D.W., Morley, A.A., Matthews. J.P. and Bishop. J.F. (1994) "The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia". Leukemia 8, 1682-1687.
  • De MeIo, M.B., Lorand-Metze, I., Lima. C.S., Saad. S.T. and Costa, F.F. (1997) "N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis". Leukemia and Lymphoma 24, 309-317.
  • Kubo, K., Naoe. T., Kiyoi. H., Fukutani, H., Kato. Y, Oguri. T., Yamamori, S., Akatsuka, Y., Kodera, Y. and Ohno, R. (1993) "Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia", Japanese Journal of Cancer Research 84, 379-387.
  • Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum. F.R., Slovak, M.L., Willman, CL. and Radich, J.P. (2001) "FLT3. RAS. and TP53 mutations in elderly patients with acute myeloid leukemia". Blood 97, 3589-3595.
  • Neubauer, A., Dodge, R.K., George, S.L., Davey, F.R., Silver. R.T., Schiffer, C.A., Mayer. R.J., Ball, E.D., Wurster-Hill, D. and Bloomfield, C.D. (1994) "Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia". Blood 83, 1603-1611.
  • MacKenzie, K.L., Doinikov. A., Millington, M., Shounan. Y. and Symonds. G. (1999) "Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice". Blood 93, 2043-2056.
  • Land, H., Parada. L.F. and Weinberg, R.A. (1983) "Cellular oncogenes and multistep carcinogenesis", Science 222, 771-778.
  • Imamura. N, Kuramoto, A., Ishihara, H. and Shimizu. S. (1993) "Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia", American Journal of Hematology43, 151-153.
  • Thiede, C., Bayerdorffer, E., Blasczyk, R., Wittig. B. and Neubauer. A, (1996) "Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping". Nucleic Acids Research 24, 983-984.
  • Sheng, X.M., Kawamura, M., Ohnishi, H., Ida, K., Hanada. R., Kojima, S., Kobayashi, M., Bessho, F, Yanagisawa, M. and Hayashi, Y. (1997) "Mutations of the RAS genes in childhood acute myeloid leukemia, myetodysplastic syndrome and juvenile chronic myelocytic leukemia". Leukemia Research 21, 697-701.
  • Kiyoi, H., Naoe. T., Nakano, Y. Yokota. S., Minami, S., Miyawaki, S., Asou, N., Kuriyama.,K., Jinnai, L., Shimazaki, C., Akiyama, H., Saito. K., Oh, H., Motoji, T., Omoto, E., Saito. H, Ohno, R. and Ueda, R. (1999) "Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia". Blood 93, 3074-3080.
  • Lee, Y.Y., Kirn, W.S., Bang, Y.J., Jung, C.W., Park, S., Yoon. WJ., Cho, K.S., Kirn. I.S., Jung, T.J. and Choi. l.Y. (1995) "Analysis of mutations of neurofibromalosis type 1 gene and N-ras gene in acute myeloid leukemia". Stem Cells 13, 556 563.
  • Koo, H.M., McWilliams, M.J., Alvord, W.O. and Vande. W.G. (1999) "Ras oncogene-induced sensitization to 1-beia-D-arabinofuranosylcytosine". Cancer Research 59, 6057-6062.
  • Koo, H.M., Gray-Goodrich, M., Kohlhagen, G., McWilliams. M.J., Jeffers, M., Vaigro-Wolff, A., Alvord. W.O., Monks, A. Paull, K.D., Pommier, Y. and Vande. W.G. (1999) "The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis", Journal of the National Cancer Institute 91, 236-244.
  • Koo, H.M., Monks, A., Mikheev, A., Rubinstein. L.V., GrayGoodrich, M., McWilliams, M.J., Alvord. W.G., Oie. H.K., Gazdar, A.F., Paull, K.D., Zarbl, H. and Vande, W.G. (1996) "Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes". Cancer Research 56, 5211-5216.
  • Morga, M.A., DoIp. O. and Reuter, C.W. (2001) "Cell-cycledependem activation of mitogen-activaled protein kirtase kinase (MEK-1 /2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling". Blood 97, 1823-1834.
  • Mizuki, M., Fensb, R., Halfter, H., Matsumura. I., Schmidt, R., Muller, C., Gruning, W., Krat2-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y. Berdel, W.E. and Serve. H. (2000) "F1t3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STATS pathways". Blood 96, 3907-3914.
  • Bradshaw, D.M. and Arceci, R.J. (1998) "Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance". Journal of Clinical Oncology 16, 3674 -3690.
  • Sabbatini, A.R., Basolo, F., Valendni. P., Mattii. L., CaIvo. S., Fiore, L., Ciardiello. F and Petrini, M. (1994) "Induction of multidrug resistance (MDR) by transfection of MCF- 1OA cell line with c-Ha-ras and c-erbB-2 oncogenes". International Journal of Cancer 59, 208-211.
  • Weinert, T. and Lydall, D. (1993) "Cell cycle checkpoints, genetic instability and cancer". Seminars in Cancer Biology 4, 129-140.
  • Sukhai, M. and Piquette-Miller, M. (2000) "Regulation of the multidrug resistance genes by stress signals". Journal of Pharmacy and Pharmaceutical Sciences 3, 268-280.
  • Baumann, B., Weber, C.K., Troppmair, J., Whiteside, S., Israel. A., Rapp, U.R. and Wlrth, T. (2000) "Raf induces NF-kappaB by membrane shuttle kinase MEKKl. a signaling pathway critical for transformation". Proceedings of the National Academy of Sciences of the USA 97, 4615-4620.
  • Chen, F., Castranova, V. and Shi. X. (2001) "New insights into the role of nuclear factor-kappaB in cell growth regulation". American Journal of Pathology 159, 387-397.
  • Daschner, P.J., Ciolino, H.P., Plouzek, C.A. and Yen. G.C. (1999) "Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells". Breast Cancer Research and Treatment 53. 229-240.
  • Kirn, R. and Beck. W.T. (1994) "Differences between drugsensitive and -resistance human leukcmic CEM cells in c-jun expression, AP-I DNA-binding activity, and formation of Jun/Fos family dimers. and their association with mleraucleosomal DNA ladders after treatment with VM-26", Cancer Research 54. 4958-4966.
  • Wanenberg, M., Ling, F.C., Schalienberg, M., Baumer, A.T., Petrau K., Hescheler. J. and Sauer, H. (2001) "Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species". Journal of Biological Chemistry 276, 17420-17428.
  • Srneeis, M.E., Haymakers, R.A., Vicrwinden, G, Pennings. A.M., Wessels, H. and de Witte. T. (1999) "Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracyclinc retention and toxicity by downregulating multidrug resistance". Blood 94, 2414-2423.
  • Braess,J.,Jahns-Streubel, G., Schoch,C.,Haase,D., Haferlach. T., Fiegl, M., Voss, S., Kern, W., Schleyer. E. and Hiddemann, W. (2001) "Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia", British Journal of Haematology 113, 975-982.
  • Richardson, D.S. and Newland, A.C. (2000) "Current perspective on the use of growth factors in the therapy of acute myeloid leukaemia malignancy". Hemalnlogy 5, 189-203.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.